STUDresearch · Non-peptide
NAD+
Also known as
Nicotinamide adenine dinucleotide · NAD plus · NAD · NAD infusions · NAD IV · NAD drip · NAD+ therapy · β-NAD · beta-NAD · Coenzyme 1 (historical label) · NAD+ injection · NAD SubQ · Niagen IV (NR IV comparator brand talk) · BR+NAD / Brain Restoration Plus NAD (addiction-clinic brand protocol)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Lots of talk
Systemic
IV / SubQ
Longevity & cellular energy
Systemic cofactor (redox, sirtuins, PARPs, mitochondria).
What people say
NAD+ is an endogenous redox coenzyme sold as IV, SubQ, IM and nasal wellness products. Direct NAD+ is distinct from oral precursors NMN and NR; small IV studies measure plasma metabolites and tolerability, not proven anti-aging outcomes.
Doses people talk about
Rate is part of the IV exposure and tolerability story. Direct IV, SubQ, IM and nasal amounts cannot be interchanged, and oral NMN or NR amounts describe different compounds.
How it may feel
IV reports include rate-sensitive abdominal anxiety, flushing, pressure and nausea, plus next-day clarity or a same-day crash. One detailed 500 mg diary initially felt a 2–3-day recharge but ended after eight drips saying the expensive course made no profound difference.
Inspected IV diary500 mg IV over 2 hours, twice weekly for 4 weeks
The same author initially described 2–3 days of energy and clarity, then after eight drips and 4,000 mg total said the expensive course produced no profound difference.
Wellness IV range~250–750 mg per infusion
A broad clinic-menu band with 500 mg common; actual infusion time and symptoms vary.
Higher IV menu~1,000–1,500 mg per visit
Intensive clinic and addiction-adjacent menu territory, generally paired with multi-hour delivery; not a large-trial standard.
Grant human pilot750 mg IV over 6 hours (~2 mg/min)
Eight healthy men received NAD+ in a small metabolome pilot; the schedule measured exposure during and shortly after infusion, not a terminal half-life or clinical benefit.
SubQ discussion~50–150 mg per injection
A common wellness-chart range, often around 100 mg, with a wider 20–200 mg band; distinct from IV exposure.
IM discussion~50–200 mg, up to three times weekly
Pharmacy-style chart discussion; less common than IV or SubQ and not directly comparable to either.
Half-life & effect duration
- Half-life in the body
- IV NAD+No settled estimate
- Felt duration people report
- Benefit claimsHours to 1–2 days; one diarist initially reported 2–3 days
- Later course updateThat diarist found no profound difference after 8 infusions
- Adverse experiencesDiscomfort during infusion or headache, chest tightness and exhaustion hours later
Cycles people discuss
Clinic culture uses clustered loading visits followed by monthly or 4–8-week maintenance. Cost, tolerability and uncertain return drive stopping; no established physiology requires a peptide-style off-cycle.
Timing
IV timing often centers on a recovery day, with food, hydration, hard workouts and night stimulants discussed around tolerability. Evening crashes and delayed symptoms also appear; SubQ morning-versus-evening preferences have no demonstrated winner.
Stacks
Vitamin drips and oral NMN or NR commonly accompany NAD+, so energy and clarity claims rarely isolate the direct molecule. Route amounts are not interchangeable.
Access talk
Three access stories: clinic IV lounges, 503A compounded SubQ/nasal via telehealth, and gray research vials.
Watch for
Cardiac red flags: Chest pressure during drip is common and often rate-related, but new/worsening chest pain, syncope, shortness of breath that does not resolve with slowing, or known cardiac disease is not a forum “just slow it” situation.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
The reviewed human IV pilot does not establish a terminal intact-NAD+ half-life.
Grant et al. administered 750 mg over six hours and sampled plasma and urine through hour eight. NAD+ and metabolites changed during and two hours after infusion, but the design did not report a terminal elimination estimate.
Tiny healthy-male pilot, empiric clinic-derived dose, short post-infusion sampling and metabolite changes rather than a full terminal phase; it does not transfer to SubQ, IM, nasal or oral precursors.
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ (opens in a new tab)Methods and results: eight healthy men received 750 mg NAD+ in saline over six hours at about 2 mg/min, three received saline, and plasma/urine NAD+ metabolites were sampled through eight hours.Small pilot with only three controls, empiric clinic dosing and two hours of post-infusion follow-up; it reports metabolome trajectories, not terminal intact-NAD+ half-life or clinical efficacy.
Felt duration people report
Felt timing is inconsistent: rate-related discomfort may occur during or hours after infusion, while claimed clarity can last days or disappear across a course.
A 500 mg/two-hour diarist first described benefits as most acute for two to three days, but after eight drips concluded there was no profound difference. Another user reported worsening headache, chest tightness and exhaustion about four hours after an IV.
Unblinded commercial care, saline and add-on vitamins, changing expectations, no product assay, no standardized outcome measure and sparse dose detail in the adverse report.
- NAD+ IV Therapy — four-week same-author diary (opens in a new tab)Original post and same-author updates from a self-described healthy, athletic 56-year-old man (5 ft 8 in, 150 lb, about 10% body fat): 500 mg over two hours twice weekly; early rate-sensitive abdominal anxiety and claimed 2–3-day recharge; week-two uncertainty; final update after eight drips/4,000 mg said no profound difference and not worth the cost.One unblinded commercial-treatment diary without control, product assay or objective efficacy endpoint; clinic advice, expense, expectancy and stable-but-unverified lifestyle factors may influence interpretation.
- NAD IV — same-day adverse experience discussion (opens in a new tab)Original post and visible same-author replies: felt fine during a first IV, then about four hours later described progressive severe headache, chest tightness and exhaustion; also disclosed concurrent detox protocols and glutathione, biotin and lysine in the visit.Dose was not stated, add-on infusions and other protocols confound attribution, and no clinical assessment or outcome update established cause or duration.
What people say
- Energy 24–72 hr post-IV: Common “recharged,” wired-clear, or less-drained claim after a single drip; confounded by saline volume, B-vitamins, rest day, caffeine, and placebo. forum
- Mental clarity / less brain fog: Top post-infusion anecdote across lounges, Reddit-style logs, and clinic testimonials. forum
- Burnout / travel / overtraining reset: Multi-day IV or inject “loading” blocks after stress, jet lag, hard training blocks, or conference weeks. forum
- Mood / motivation lift: Some report improved drive or less flat affect after loading; causality usually unclear. anecdote
- IV vs daily precursors (community narrative): IV cast as high-intensity reset; NMN/NR as daily floor—not interchangeable proof of superior longevity. forum
- Athletic / recovery adjacency: Discussed near deloads, sleep cleanup, zone-2 base building, and mito stacks; hard to isolate from lifestyle confounds. forum
- What marketing overclaims: “Reverse aging,” guaranteed addiction cure, or permanent energy from one drip—community volume far exceeds outcome-trial support. forum
- Nasal maintenance claim: 2026 telehealth copy frames sprays as daily needle-free support; user logs more often say subtle-to-nothing vs a lounge IV. forum
- Addiction-clinic history: Older multi-day high-dose IV NAD+ protocols (including branded BR+NAD-style courses with vitamins/amino acids) for alcohol/opioid/stimulant withdrawal and craving support—clinic-reported and observational, not gold-standard addiction RCTs proving superiority over standard care. trial
- Precursor NAD rise (strongest human signal): Oral NR and NMN trials show dose-related increases in whole-blood NAD+ / NAD metabolome markers over days–weeks. trial
- NR oral dose-response examples: Multi-week NR trials commonly use ~100–1,000 mg/day; published dose-ranging patterns include roughly ~+20–25% (100 mg), ~+50% (300 mg), and ~+140% (1,000 mg) class whole-blood NAD+ rises vs baseline in 8-week designs (exact % vary by assay and paper). trial
- NMN oral dose examples: Common trial anchors ~250 mg/day; dose-ranging bands 300–900 mg/day (and higher short-term safety windows ~1,000–1,250+ mg/day) report large blood NAD rises and exploratory walk/insulin/aerobic endpoints—not lifespan proof. trial
- NR vs NMN head-to-head (oral): A short multi-arm precursor comparison reported ~1 g/day NR or NMN for ~14 days each roughly doubled circulating NAD+ while nicotinamide at a lower tested dose did not match that rise—still not a longevity outcome trial. trial
- Animal aging / mito models: NAD boosting (often via precursors) cited for mitochondrial and aging-related phenotypes in rodents—not human lifespan proof. animal
- Grant 2019 IV plasma metabolome pilot: Continuous IV NAD+ ~750 mg over ~6 h (~2 mg/min / ~3 μmol/min) in healthy men raised plasma NAD+ ~398% by end of infusion vs baseline, with parallel rises in nicotinamide, ADPR, and methylnicotinamide; plasma NAD stayed elevated at ~8 h (2 h post-infusion) in that design. trial
- Cognitive pilot adjacency: Small work measuring cognitive performance around IV NAD+ PK protocols exists (e.g., Gibson et al. poster/pilot framing)—signal and controls are limited; not a large cognition RCT. trial
Doses people talk about
- IV session totals (wellness): Commonly ~250–750 mg per infusion; many lounges anchor ~500 mg; menus often list 250 / 500 / 1,000 mg tiers; beginners sometimes start ~100–200 mg to test tolerance before climbing. forum
- IV high-end session: ~1,000–1,500 mg per visit appears on intensive/fatigue/addiction-adjacent menus—almost always with multi-hour slow rates. forum
- IV monthly caps (marketing): Some chain language discusses multi-session monthly totals up to ~3,000 mg across visits—vendor-specific, not a trial standard. forum
- IV loading — Hydration Room–style example: ~5 IV treatments within ~10 days, then maintenance every ~4–6 weeks (clinic marketing). forum
- IV loading — stepped total example: e.g., ~1,500 mg total across ~7–10 days as 250 mg then 500 mg then 500 mg then 250 mg on separate days; follow-ups sometimes ~250 mg weekly for a few weeks then monthly. forum
- IV loading — short consecutive: Daily infusion for ~4 days then monthly maintenance; or ~4 infusions over ~2–3 weeks; or 2–3× weekly during a loading month. forum
- IV loading — weekly series: ~250–500 mg twice weekly for ~4 weeks, then weekly for ~4–8 weeks, then spaced maintenance—one published clinic-style template among many. forum
- IV maintenance spacing: Often monthly or every ~4–8 weeks after load; some stay weekly during a series then space out; others use biweekly. forum
- IV infusion duration / rate (clinic rules of thumb): Faster rate → more flush, chest pressure, GI. Common published clinic heuristics include ~125 mg/hour style pacing (e.g., ~250 mg ≈ 2 h, ~500 mg ≈ 4 h, ~1,000 mg ≈ 8 h), or “at least ~2 h for 250 mg and ~4+ h for 500 mg+.” forum
- SC injectable (common wellness band): Often ~50–150 mg per injection; many protocols cluster ~100 mg; wider band ~20–200 mg appears across clinic charts. forum
- SC frequency: Typically 1–3×/week maintenance; many say 2–3×/week; some use daily micro-doses ~25–50 mg; weekly-only SOPs also exist. forum
- SC weekly SOP example: Start ~50 mg SC once weekly × 4 weeks → increase to ~100 mg once weekly if tolerated; some SOPs cap at ~100 mg weekly. forum
- SC intensive load talk: Some clinician blogs discuss ~100–200 mg SC daily for ~7–14 days as a loading alternative to multi-day IV—less standardized and more side-effect risk than low-and-slow. forum
- IM injection: Often ~50–200 mg discussed; up to ~3×/week in pharmacy-style charts; less common than IV/SC in modern wellness threads. forum
- Nasal alternative strength talk: Other compounders discuss ~25–50 mg per spray formulations with 1–2 sprays per nostril once or twice daily. forum
- Oral NAD+ products: Marketed as capsules/liquids but often deprioritized vs NMN/NR in bioavailability debates; not treated as equivalent to IV NAD+ mg. forum
- Sublingual precursor niche: NMN/NR sublingual/troche marketing exists separately from injectable NAD+; absorption claims exceed controlled tissue-NAD proof. forum
- Load vs maintain logic: More frequent higher exposure early, then spaced IV or lower SC / daily oral precursors—not endless mg climb. forum
- Cost context (community reality check): Single IV sessions commonly discussed roughly ~$200–$800+ (wide metro/dose range; extremes higher); loading packages multi-thousand dollars—drives SC/precursor substitution talk. forum
- Purity / label flag: Compounded and research-chem mg claims are not interchangeable without independent testing; clinic vs gray-market concentrations and BUDs differ. forum
- Three-camp 2026 (do not swap mg): Lounge IV ~250–750 mg/session (500 mg is the middle); home SubQ ~50–150 mg, often ~100 mg, 1–3×/week; nasal daily low-mg sprays as “maintenance.” Milligrams are not interchangeable across routes. forum
- Nasal-bioavailability lore: Clinic pages quote wide figures (sometimes ~20–50%). Those are unsourced vs IV; no head-to-head human PK. forum
- Grant 2019 research anchor: ~750 mg NAD+ IV over ~6 h at ~2 mg/min (≈ 3 μmol/min) in a small healthy-male pilot—used because it reflected common clinic empiric dosing at the time. trial
- Reyna / real-world NAD+ IV vs NR IV (2026 Frontiers pilot): ~500 mg IV NAD+ daily for 4 consecutive days (n=6 NAD+ arm) vs ~500 mg IV NR (n=8); NAD+ arm reported moderate–severe infusion symptoms and longer average infusion time (~97 ± ~56 min vs ~37 min for NR). trial
- Oral precursors (not NAD+): NR often ~300–1,000 mg/day in trials/consumer use (trial bands include 100 / 300 / 1,000 mg); NMN often ~250–1,000 mg/day community band with trial anchors at 250 mg and dose-ranging 300–900+ mg. trial
- Framing: Clinic menus, compounding-pharmacy charts, and community discussion ranges only—not advice, not prescriptions, not standardized medical dosing. Protocols diverge hard across brands. forum
- Hawkins / acute Niagen IV vs NAD+ IV pilot (preprint framing): Single ~500 mg IV arms; NR IV faster/better tolerated with ~20.7% whole-blood NAD rise by ~3 h outperforming NAD+ IV and oral NR at that snapshot in the reported design. trial
How it may feel
- During IV (rate-dependent): Flushing, facial warmth, chest pressure/tightness, throat discomfort, nausea, abdominal cramping, muscle cramps, urge to stool/diarrhea, anxiety, elevated heart rate, lightheadedness—classically eases when the nurse slows or pauses the drip. forum
- First-session surprise: Many first-timers underestimate how uncomfortable a “fast” NAD drip feels compared with a standard vitamin bag; multi-hour appointment time is the norm, not a 20-minute Myers push. forum
- Same day post-IV: Wired-tired comedown, early “clear head,” headache, or need to rest/hydrate/eat; many treat the day as a recovery day rather than a training day. forum
- 24–48 hours: Energy and clarity anecdotes cluster here after a single well-tolerated session. forum
- Days 2–7: Subjective lift often fades toward baseline without another session, SC maintenance, or daily oral precursors. forum
- Loading week (clinic scripts): Daily, every-other-day, or multi-session loads (e.g., 4–10 visits over 1–3 weeks, or ~5 drips within ~10 days) feel stronger than one drip; slower rates improve tolerance as dose climbs. forum
- Weeks 2–4: Occasional IV/SC plus daily NMN/NR often credited for steadier energy vs one-off drips alone. forum
- SC titration weeks: Start low (tens of mg), step up as tolerated over sessions—site comfort, nausea, and “wired” feel guide pace more than fixed calendar rules. forum
- Post-IV crash: Wired-clear then wiped later the same day — or a 24–72 h lift then fade — is a common drip story, confounded by saline, vitamins, and a rest day. forum
- SubQ vs IV feel: Home shots are usually milder same-day (site sting, light flush/nausea); next-day “cleaner energy” is the typical log. Accidental vein hits can feel suddenly IV-like (anxiety, chest tightness). anecdote
- Nasal: Irritation, drip taste, or nothing for days–weeks is more common in logs than an IV-style rush. forum
Around the dose
- Timing report: One first-IV account described severe headache, chest tightness, and exhaustion starting about four hours later; concurrent detox protocols and add-on infusions confound timing and causality. forum
- Training: Some time IV/injectable away from an all-out session because of flush/cramp talk. Oral is more flexible. forum
- After: Hydration and not stacking a night stimulant on the same day. forum
- IV day = recovery day: Fast drips plus a hard workout or a night stimulant is a common “why do I feel awful” stack. forum
- Hydrate / eat: Empty-stomach fast drips are blamed for worse nausea and cramping. forum
- Crash window: Some feel wiped the evening after an IV even if the bag felt “clear.” forum
Cycles people discuss
- IV loading blocks: Several sessions over ~1–2 weeks or ~10 days (e.g., 4–10 visits, or ~5 within 10 days) in common lounge scripts. forum
- IV consecutive short course: ~4 daily drips then jump to monthly maintenance appears on some menus. forum
- IV series alternative: Weekly ~500–750 mg for ~4–6 weeks then monthly maintenance appears in some physician-protocol pages. forum
- IV twice-weekly load then taper: e.g., 2×/week for a month → weekly → every 4–6 weeks—varies by brand. forum
- IV maintenance: Monthly or every ~4–6 (sometimes 4–8) weeks after load; many add oral precursors between visits. forum
- SC micro-cycles: Multi-day consecutive injects or several-times-weekly SC instead of one big IV; some intensive scripts discuss higher daily inject totals for a week or two then step down—clinic-dependent and not standardized. forum
- SC titration then hold: 1–2 months at working dose (e.g., ~2–3×/week) then optional lower maintenance frequency appears in compounding-pharmacy style guides. forum
- Addiction-clinic historical courses: Multi-day consecutive high-dose IV—commonly discussed as ~4–10+ days, multi-hour drips (often ~5–10 h), daily totals in the hundreds to ~1,000–1,500+ mg range (BR+NAD-style write-ups cite ~500–1,500 mg/day for ~8–10 consecutive days with adjunct vitamins/amino acids)—then taper/maintenance; distinct from wellness “top-off” culture. forum
- Time off drivers: Cost, access, drip discomfort, diminishing subjective return, and life logistics drive breaks more than a fixed scientific off-cycle rule. forum
- No mandatory off-cycle science: Unlike AAS/peptide “PCT” culture, NAD+ community rarely invents a required washout—people stop when money, sides, or boredom win. forum
- Oral precursors: Usually open-ended daily NMN/NR, not strict on/off peptide cycles; fair trial windows often 4–12 weeks for judging blood NAD or subjective energy. trial
- Older published addiction-style schedules (secondary sources): e.g., 500–1,000 mg IV daily × 4 days → twice weekly for a month → twice monthly; other clinic lore cites ~800–1,800 mg/day over 3–8 h for ≥1 week—historical/clinic-reported, not modern RCT standards. trial
Timing
- Why multi-hour IV: Slow drip for tolerance and to avoid dumping dose faster than clearance/uptake—not a bolus and not proof of long multi-day plasma half-life. forum
- Feel vs blood levels: “Charged” feel claimed hours to 1–2 days after acute plasma snapshots would be expected to fall—anecdotal, confounded by sleep/hydration/placebo. anecdote
- SC timing: Morning vs evening logs exist; no controlled head-to-head for outcomes. Site absorption is slower than IV peak exposure by design. forum
- Rate ≠ elimination half-life: Infusion side effects track delivery speed/tolerance more than a published terminal t½ number people can quote from a label. forum
- PK honesty: Solid multi-dose human IV NAD+ PK tables are thinner than marketing implies; small pilots dominate. trial
- Grant 2019 timing shape: During continuous ~6 h infusion of ~750 mg at ~3 μmol/min, plasma NAD+ and primary metabolites (NAM, ADPR, meNAM) did not rise for the first ~2 h—consistent with rapid complete removal/sequestration—then rose sharply by end of infusion (~398% plasma NAD+; ~409% NAM; ~393% ADPR; ~350% meNAM vs baseline at 6 h). trial
- Post-infusion (Grant): At ~8 h (2 h after stop), plasma NAD+ remained elevated vs baseline/control in that pilot; NAM/ADPR differences vs control largely narrowed while meNAM stayed high; plasma NMN rose significantly only at the 8 h mark (~472%). trial
- Urine (Grant): NAD+ and meNAM urinary excretion rates peaked around end of infusion (~538% NAD+ excretion-rate rise at 6 h vs early timepoint); NAM urine excretion did not show a matching significant rise. trial
- Extracellular cleavage talk: Parallel NAM + ADPR rise is discussed as consistent with NADase/glycohydrolase activity (e.g., CD38) cleaving circulating NAD+; pyrophosphatase paths to NMN/AMP also discussed. trial
- Precursor timing: Oral NR/NMN raise NAD markers over hours after a dose and over days–weeks of repeated dosing; daily use matches short precursor kinetics better than monthly IV alone. trial
- NR IV pilot note: In one acute comparison, NR IV raised whole-blood NAD ~20.7% by ~3 h and finished faster/more tolerably than NAD+ IV in that design—does not settle long-term superiority or tissue half-life. trial
- Reyna multi-day note: Four consecutive commercial-setting drips still lacked robust whole-blood NAD assay success in that report; tolerability/time-on-drip were the cleaner signals. trial
More on what it is
- Why people want it: Age-related NAD+ decline is framed as a fixable bottleneck for energy, recovery, cognition, and longevity—amplified by IV-lounge marketing and precursor hype. forum
- IV / inject vs oral path: Direct NAD+ = IV, SC, IM, or nasal in wellness talk; oral NAD+ is often deprioritized because the intact dinucleotide is a poor oral uptake candidate—most oral users take precursors NMN or NR instead. forum
- Mechanism talk (simplified): Supports mitochondrial electron transport (as NAD+/NADH), DNA-repair enzyme activity (PARPs), and sirtuin signaling; forums often oversell this as a single “cellular recharge” switch. forum
- 2026 nasal vs IV vs SubQ fight: NAD+ is ~663 Da, so it sits under the “nasal might absorb” ~1 kDa lore — but it is a charged, hydrophilic dinucleotide. Clinic blogs sell daily sprays as IV-lite; skeptics say there is no peer-reviewed human nasal PK, while IV has a small Grant 2019 plasma-rise pilot and SubQ is the cheaper at-home compromise. forum
- What it is: Endogenous coenzyme (oxidized form of NAD) used in hundreds of redox reactions and as a consumed substrate for sirtuins, PARPs, CD38, and related enzymes; sold as clinic IV drips, compounded injectables, nasal sprays, and (less favored) oral products. trial
- Evidence posture: Oral NR/NMN trials reliably raise blood NAD+ / NAD-metabolome markers; human IV NAD+ has small PK/safety/tolerability pilots and historical addiction-clinic reports—not large anti-aging outcome RCTs. trial
- IV vs precursor framing: Clinics sell intense multi-hour IV “boosts”; daily NMN/NR is cast as steady maintenance—head-to-head longevity outcomes are not established. forum
- NR IV comparison talk: Small pilots comparing IV NAD+ vs IV NR found worse infusion tolerance and longer drip times with NAD+, and in an acute design clearer whole-blood NAD rise with NR IV at ~3 h—does not settle long-term superiority. trial
- Not the same as: Not a peptide, not FDA-approved as an anti-aging drug, not interchangeable mg-for-mg with niacin, niacinamide (NAM), NMN, NR, or NADH. trial
- Research-only framing: Clinic marketing and forum protocols are not medical advice; purity, concentration, infusion rate, and medical screening vary widely across lounges and gray-market kits. forum
- Not a July 2026 PCAC peptide: The July panel was BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Epitalon, and Semax. NAD+ access talk is compounded wellness/telehealth and gray vials, not that vote. trial
Stacks
- NAD+ IV + Myers / B-complex / multivitamin drip: Same-visit vitamin bags are extremely common; confounds single-agent credit for energy. forum
- NAD+ + glutathione (IV push or separate bag): Popular “detox / redox” clinic pair; often same-day or adjacent visits. forum
- IV/SC NAD+ + daily NMN or NR: Precursors between clinic sessions as maintenance bridge—most common hybrid longevity script. forum
- Methyl-support with precursors: TMG/betaine, methylfolate, B12 discussed with high-dose NMN/NR because nicotinamide clearance uses methylation pathways—more precursor lore than IV-specific, but often runs in the same stack. forum
- Mito stack: CoQ10, PQQ, sometimes urolithin A or Ca-AKG paired in longevity forums. forum
- Methylene blue adjacency: Same mitochondrial-electron conversation; some stack both; evidence for combo protocols is thin and dosing of methylene blue is its own risk surface. forum
- Peptide / mito peptide adjacency: SS-31 (elamipretide-class talk), MOTS-c, and related “mito repair then fuel” sequences appear in peptide circles; highly confounded. forum
- Resveratrol / sirtuin talk: Older Sinclair-adjacent pairing with NAD-pathway precursors more than with IV NAD+ itself. forum
- Apigenin / CD38 talk: Some biohackers add apigenin as a theoretical CD38-modulating NAD-sparing stackmate—mechanistic forum lore, not a proven IV companion protocol. forum
- Performance adjacency: Near GH-secretagogue peptides, creatine, deloads—lifestyle confounds dominate. forum
- Addiction-clinic adjuncts (historical BR+NAD-style): IV NAD+ plus vitamins, oral amino acids, NAC, and variable PRN meds over multi-day courses—bundled care, not NAD+ alone. forum
- Lifestyle stack that forums credit: Sleep, zone-2 cardio, protein, alcohol reduction, and stress load often get equal or more credit when energy improves. forum
- Nasal as IV-bridge: Some use a daily spray between monthly drips or weekly shots — convenience stack, not a PK protocol. forum
Access talk
- Three access stories: clinic IV lounges, 503A compounded SubQ/nasal via telehealth, and gray research vials. forum
- Not FDA-approved as an anti-aging drug and not on the July 2026 peptide PCAC seven. trial
- Quality watch: 2025 Class I endotoxin recall plus FDA warnings about food-grade NAD+ in sterile compounding are what careful threads now cite. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Vasodilation / hemodynamic talk: Rapid infusion linked to flushing, possible BP drop, tachycardia, chest tightness—screening for cardiac risk is clinic practice, not a DIY rate tip. forum
- Injection site: SC/IM soreness, redness, bruising, or warmth; higher concentration/volume can sting more. forum
- Post-session crash: Headache, lightheaded, wired-tired, or tired comedown even after a tolerated drip. forum
- Nasal local effects: Irritation, drip taste, congestion, or runny nose reported with sprays (product-dependent). forum
- Methylation / nicotinamide clearance talk: High precursor loads discussed with methyl-donor support (TMG, B vitamins)—mechanistic caution more than proven clinical harm for everyone. forum
- Cost / access pressure: Expensive lounges push gray-market self-inject without monitoring, verified concentration, or sterile technique. forum
- Source quality: Compounded/research-chem contamination, mislabel, wrong concentration, degraded product, expired BUD. forum
- Cardiac red flags: Chest pressure during drip is common and often rate-related, but new/worsening chest pain, syncope, shortness of breath that does not resolve with slowing, or known cardiac disease is not a forum “just slow it” situation. forum
- Confounded credit: Same-day vitamins, placebo, rest day, saline volume, and lifestyle changes frequently co-travel with “NAD fixed me” stories. forum
- Addiction-care caution: NAD+ IV is not a substitute for evidence-based detox/medically supervised withdrawal care; clinic testimonials ≠ controlled cure rates. forum
- Nasal is not “IV in your nose.” Charged dinucleotide + no published human nasal PK is the skeptic line; irritation is the reliable local effect. forum
- Accidental IV from SubQ: 2026 logs of nicking a vessel → sudden rush of anxiety/chest tightness. anecdote
- IV rate-related cluster: Flushing, chest pressure/tightness, nausea, abdominal cramping, diarrhea/urge to stool, muscle cramps, elevated heart rate, dizziness, anxiety, throat discomfort, headache—slow or pause the drip is the standard clinic response. trial
- Reyna multi-day NAD+ IV arm: Moderate–severe symptoms reported with ~500 mg IV NAD+ across multi-day course (GI, HR up, throat pain, chest pressure); longer average infusion times than NR IV; 30-day routine safety labs did not show meaningful clinical harm in that small pilot. trial
- Hawkins acute comparison narrative: NAD+ IV arm anecdotes include anxiety, headaches, nausea, chest tightness, hot flashes, stomach cramping, diarrhea, and mid-session bathroom urgency more often than NR IV’s milder tingling/pressure reports. trial
- Grant 2019 at slow rate: No adverse events observed during ~750 mg / 6 h infusion in that small healthy-male pilot; minor non-clinically-significant liver-marker shifts (e.g., slight bilirubin up; GGT/LD/AST down). Slow rate ≠ proof all clinic rates are comfortable. trial
- Oral precursors GI: Mild GI upset at higher NMN/NR doses in some users; generally better tolerated than acute IV NAD+ effects. trial
- Safety gap: Small pilots without serious lab events ≠ long-term high-dose IV safety proof or efficacy for aging/addiction claims. trial
- Regulatory / marketing gap: Not FDA-approved as an anti-aging drug; wellness claims outrun large outcome trials. NMN as a separate oral ingredient had a US dietary-supplement status fight (2022 exclusion narrative, later FDA clarification that NMN is not excluded from the supplement definition)—still not an aging-drug approval. trial
- 2025 injectable quality scare: FDA classified a Class I recall of compounded NAD+ injection lots (GenoGenix; elevated endotoxin) in October 2025 after a July voluntary recall. Separate FDA reminder: do not use food-grade NAD+ to compound sterile injectables; adverse-event reports included severe chills, shaking, vomiting, and fatigue. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.